Metforal

Metformin, the active ingredient in Metforal, is a Biguanide presented as an oral tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metforal belongs to the biguanide class and is indicated for disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves blood glucose control by lowering hepatic glucose output and enhancing peripheral insulin sensitivity.

Metforal may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Vitamin B12 deficiency: long‑term use may reduce absorption. - Pancreatitis: inflammation of the pancreas. - Hypoglycaemia: usually when combined with other antidiabetics.

Metforal requires careful monitoring and patient education to minimise risks.

- Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function monitoring: contraindicated in acute liver disease. - Lactic acidosis risk: discontinue before radiologic contrast studies. - Alcohol consumption: limit intake to reduce acidosis risk. - Elderly patients: start at lower dose and monitor tolerance. - Store at room temperature: keep in original container, protect from moisture and heat.

Metforal can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; withhold metformin before and after the procedure. - Cimetidine: may raise metformin plasma concentrations. - Acute heart failure: can precipitate renal dysfunction and lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - Other antidiabetic agents: risk of additive hypoglycaemia. - Corticosteroids: may raise blood glucose, requiring dose adjustment.